Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The current management of thalassemia includes regular transfusion programs and chelation therapy. It is important that physicians be aware that endocrine abnormalities frequently develop mainly in those patients with significant iron overload due to poor compliance to treatment, particularly after the age of 10 years. Since the quality of life of thalassemia patients is a fundamental aim, it is vital to monitor carefully their growth and pubertal development in order to detect abnormalities and to initiate appropriate and early treatment. Abnormalities should be identified and treatment initiated in consultation with a pediatric or an adult endocrinologist and managed accordingly. Appropriate management shall put in consideration many factors such as age, severity of iron overload, presence of chronic liver disease, thrombophilia status, and the presence of psychological problems. All these issues must be discussed by the physician in charge of the patient's care, the endocrinologist and the patient himself. Because any progress in research in the field of early diagnosis and management of growth disorders and endocrine complications in thalassemia should be passed on to and applied adequately to all those suffering from the disease, on the 8 May 2009 in Ferrara, the International Network on Endocrine Complications in Thalassemia (I-CET) was founded in order to transmit the latest information on these disorders to the treating physicians. The I-CET position statement outlined in this document applies to patients with transfusion-dependent thalassemia major to help physicians to anticipate, diagnose, and manage these complications properly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA
Pippard, M. J., Warner, G. T., Callender, S. T., & Weatherall, D. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92175-5 · Cited by 419
Practical management of iron overload
Porter, J. B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03195.x · Cited by 378 · cited 1×
“Current practice is to begin iron chelation therapy when the serum ferritin levels reach 1000 ng/ml or when child reaches 3 years of age or has received about 10‐20 transfusions.[2,3,13]”
BackgroundResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Laboratory Investigation of Hemoglobinopathies and Thalassemias: Review and Update
Clarke, G. M., & Higgins, T. N. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.8.1284 · Cited by 353
Thalassemia — a global public health problem
Weatherall, D. J., & Clegg, J. B. (1996) · Nature Medicine · doi:10.1038/nm0896-847 · Cited by 250 · cited 1×
“107808 are the most commonly inherited genetic disorders, with some 240 000 infants born annually with major hemoglobinopathies and at least 190 million carriers worldwide.[1,2]”
BackgroundPathophysiology of Iron Overloada
HERSHKO, C., LINK, G., & CABANTCHIK, I. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10475.x · Cited by 248
Farmaki, K., Tzoumari, I., & Pappa, C. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.03.007 · Cited by 94 · cited 1×
“[3,13‐15] Recently, oral monotherapy with deferasirox has been used, as it is equally effective to DFO and deferiprone.[16]”
MethodDeferasirox for managing iron overload in people with thalassaemia
Bollig, C., Schell, L. K., Rücker, G., Allert, R., Motschall, E., Niemeyer, C. M., Bassler, D., & Meerpohl, J. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007476.pub3 · Cited by 76
Growth and puberty in thalassemia major.
Raiola, G., Galati, M. C., Sanctis, V. D., Nicoletti, M. C., Pintor, C., Simone, M. D., Arcuri, V. M., & Anastasi, S. (2003) · PubMed · Cited by 65
Self-citation
Cited by
Farmakis, D., Porter, J., Taher, A., Domenica Cappellini, M., Angastiniotis, M., Eleftheriou, A., & Taskforce, F. T. 2. T. G. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000732 · Cited by 307
Self-citation
Metadata
- Authors
- De Sanctis, V., Soliman, A., Elsedfy, H., Skordis, N., Kattamis, C., Angastiniotis, M., Karimi, M., Yassin, M. A. D., El Awwa, A., Stoeva, I., Raiola, G., Galati, M., Bedair, E., Fiscina, B., & El Kholy, M.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2013
- Volume
- 17
- Issue
- 1
- Pages
- 8
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W1984997586
- Cited by
- 170
- References
- 17
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. https://app.cochat.ai/papers/10.4103/2230-8210.107808
- The paper
- De Sanctis, V., Soliman, A., Elsedfy, H., Skordis, N., Kattamis, C., Angastiniotis, M., Karimi, M., Yassin, M. A. D., El Awwa, A., Stoeva, I., Raiola, G., Galati, M., Bedair, E., Fiscina, B., & El Kholy, M. (2013). Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian Journal of Endocrinology and Metabolism. https://doi.org/10.4103/2230-8210.107808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.